Agilent and Incyte Collaborate on CDx for Hematology and Oncology
Agilent will expand its CDx portfolio with novel biomarkers and Incyte will leverage Agilent’s expertise in IVD assay development.
Read MorePosted by Andy Lundin | Jan 31, 2024 | Cancer, Hematology & Serology |
Agilent will expand its CDx portfolio with novel biomarkers and Incyte will leverage Agilent’s expertise in IVD assay development.
Read MorePosted by Andy Lundin | Jan 24, 2024 | Prenatal Testing |
Natera has acquired certain assets from Invitae relating to its non-invasive prenatal screening and carrier screening business.
Read MorePosted by Chris Wolski | Jan 11, 2024 | Lab Automation |
Swedish Hospital laboratory has worked to strategically use automation and non-technical staff to ease the burden on technical employees.
Read MorePosted by Andy Lundin | Jan 4, 2024 | Hematology Instrumentation, Lab Automation |
The platform offers a flexible modular hematology solution that is fully scalable with myriad configurations for mid to large-scale labs.
Read MorePosted by Andy Lundin | Jan 3, 2024 | Breast |
A new test uses AI to see whether a patient is positive for cancer as soon as detectable by mammogram or earlier, and before symptoms arise.
Read More